1.1Acidic liquid formulation
Dissolve the compound in an aqueous buffer at a pH that protonates the carboximidamide group. Set the concentration below the measured equilibrium solubility at the formulation pH and storage temperature.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Dissolve the compound in an aqueous buffer at a pH that protonates the carboximidamide group. Set the concentration below the measured equilibrium solubility at the formulation pH and storage temperature.
Mount an isolated crystal on a rotation stage and collect diffraction images at successive orientations. Index the discrete reflections to determine the unit cell, then refine the atomic positions to determine the molecular packing.
Convert the positions of the three diffraction peaks to lattice spacings using Bragg’s law and the measurement wavelength. Transform the angular tolerance bounds into spacing intervals and compare samples directly in spacing units.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A powder diffractometer uses a Co Kα source in place of the Cu Kα source. The operator calibrates the angular axis with a silicon reference powder and scans the crystalline specimen. Software converts the measured peak centers to interplanar spacings using Bragg's law and compares them with the spacings derived from the three Cu Kα reference positions. The central reference positions are approximately 16.9°, 27.8°, and 31.1° in 2θ with Co Kα radiation.
A Cu Kα diffractometer scans three 2θ windows from 14.0° to 15.0°, 23.4° to 24.4°, and 26.2° to 27.2°. The instrument collects counts in 0.02° steps with a dwell time of 4 seconds per step. A local peak fit estimates the center of each reflection and checks it against the corresponding reference position within ±0.2°.
A Cu Kα powder diffractometer fitted with an environmental chamber holds the crystalline powder in a shallow sample cup behind an X-ray-transparent window. A gas mixer supplies dry and humidified gas to the chamber while a humidity sensor measures relative humidity near the specimen. The instrument collects a baseline pattern and repeats the scan at each programmed humidity plateau after the chamber stabilizes. The resulting series tracks the three reference reflections and records additional peaks that appear during exposure.
A solid-state testing workflow pairs a Cu Kα diffractometer with a temperature-controlled stirred dissolution vessel and a liquid chromatograph. One aliquot of the crystalline powder supplies the starting diffraction pattern, and a second aliquot enters an acidic buffer in the vessel. Filtered liquid samples collected at timed intervals pass to the chromatograph, which measures dissolved compound concentration against a calibration curve. At the endpoint, any remaining solids are recovered by filtration and measured by diffraction to check whether the three reference reflections persist.
A motorized sample changer presents barcoded powder mounts to a Cu Kα diffractometer. Software corrects the angular offset using a separately measured silicon reference and fits peaks near 14.5°, 23.9°, and 26.7° in 2θ. It records a three-peak match when all fitted centers lie within ±0.2° of their targets and each peak exceeds a preset signal-to-noise threshold. It saves the raw pattern, fit results, and sample identifier for review.
Back-load the crystalline powder into a flat holder and level the exposed surface with minimal compression. Collect the reflection pattern with Cu Kα radiation and verify the three specified peak positions.
Place a thin layer of crystalline powder between polymer films and illuminate it in transmission with Cu Kα radiation. Use a position-sensitive strip detector to collect the angular profile and verify peaks near 14.5°, 23.9°, and 26.7° 2-theta within the stated tolerances.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The crystalline Form D of entacapone of claim 41, having characteristic X-ray diffraction peaks at 2-theta values of about 6.820, 14.780, 15.540, 16.540, 16.880, 17.960, 20.760, 21.400, 21.540 and 22.200.A · US 2008/0004343 A1 · claim 42
The crystalline ansolvate of claim 1, characterized by X-ray powder diffraction peaks (Cu Kα radiation) of 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ).B · US 9,447,071 B2 · claim 4
An empty cell means only that no passage was reproduced there.
Crude Entacapone synthesized from conventional solvents, such as hydrocarbons, alcohols or esters, e.g., benzene, toluene, methanol, ethanol, ethyl acetate, isopropyl acetate, etc., provide a very complicated mixture of different geometric isomers and/or polymorphic forms are generally obtained that interfere with the characterization and standardization of the drug substance.A · US 2008/0004343 A1 · ¶
The present invention relates to stable crystalline polymorphic Form C and Form D of Entacapone, (E)-N,N-iethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and an efficient method for their preparation.A · US 2008/0004343 A1 · ¶ 2
However, the art remains unable to predict which crystalline form of an agent will have a combination of the desired properties and will be suitable for human administration, and how to make the agent in such a crystalline form.B · US 9,447,071 B2 · ¶ 7
Accordingly, the free base of Compound 1 provides a stabler chemical entity compared to the corresponding HCl or sulfate and such other salt.B · US 9,447,071 B2 · ¶ 8
patent.fyi, US 2026/0356800 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356800/, SHA-256 4fd34325e1a6365bf6f65f4013c5ac33e6e65721fbc78f3347e7d33ba23e70e3